title: Adjuvant therapy for melanoma: How should we respond to high-dose interferon?
authors.affiliation: Oncology Centre, Addenbrooke's NHS Trust, Cambridge, UK.
authors.forename: P G
authors.initials: PG
authors.lastname: de Takats
authors.forename: M V
authors.initials: MV
authors.lastname: Williams
authors.forename: R
authors.initials: R
authors.lastname: Hawkins
mesh_terms: D000328:Adult; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008545:Melanoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins; D015996:Survival Rate
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins